Replies to post #365528 on Anavex Life Sciences Corp (AVXL)

[Steady_T]

Your theory on what is going to be required for Anavex to expand makes no sense to me.

For Anavex to get 2-73 on the market for the rare diseases will not be expensive. Marketing costs will be moderate to minimal since at present there are almost no drug options for the people suffering from those diseases. The support organizations will get the word out and the specialists Drs will be made aware by the support orgs. Distribution is not an issue. Existing drug distribution companies will pick up 2-73 just like any other drug they distribute.

Missling has already said that Anavex will partner for the large market indications like AD, PDD, PD etc. so the costs to Anavex will be negative. Whoever partners will be paying Anavex and providing the sales, marketing, and distribution services.

So where are all of these costs you expect going to come from that will require massive dilution to pay for?

[Bourbon_on_my_cornflakes]

Total Rubbish: If for some odd reason Anavex does not sell to an established big pharma with experience rolling out drugs on a large scale worldwide it will dilute like crazy.

ONE BIG SCORE, either alz or PD, will provide at least $1 billion a year in cash flow, making futher dilution unnecessary. And that score could happen in 2023 , while we still have less than 80 million shares.

With the massive cash flow, AVXL will be buying back shares, not issuing them.